Gene: SCN9A

6335
ETHA|FEB3B|GEFSP7|HSAN2D|NE-NA|NENA|Nav1.7|PN1|SFNP
sodium voltage-gated channel alpha subunit 9
protein-coding
2q24.3
Ensembl:ENSG00000169432 MIM:603415 Vega:OTTHUMG00000154044 UniprotKB:Q15858
NG_012798.1
PubMed
0   ANCO-SNPs
ND
1   
NA (AD)  1.122e-1 (ND)   (Frontal_Cortex)
1.449e-1 (AD)  2.641e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
KLHL10.759
CXorf570.74
SLITRK60.725
SLC5A70.702
HTR2C0.701
TH0.697
IL13RA20.694
GRID20.692
IRX10.691
KLHL130.689

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
ZNF98-0.38
OTX1-0.321
OAF-0.312
PYGM-0.311
RLBP1-0.308
RNF43-0.303
TNNT1-0.293
DIO2-0.29
NXNL1-0.285
SLC6A13-0.281

Drugs/Compounds

ID Drug Name Drug Type CAS Num Status Role
DB00243RanolazineSmall Molecule95635-55-5Approved|InvestigationalTarget
DB00281LidocaineSmall Molecule137-58-6ApprovedTarget
DB00909ZonisamideSmall Molecule68291-97-4Approved|InvestigationalTarget
DB06201RufinamideSmall Molecule106308-44-5ApprovedTarget
DB06218LacosamideSmall Molecule175481-36-4ApprovedTarget
DB00313Valproic AcidSmall Molecule99-66-1Approved|InvestigationalTarget
DB05541BrivaracetamSmall Molecule357336-20-0Approved|InvestigationalTarget
ID Drug Name Action PubMed
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCN9A mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCN9A mRNA"27188386
D000082AcetaminophenAcetaminophen results in increased expression of SCN9A mRNA29067470
D016604Aflatoxin B1Aflatoxin B1 results in decreased expression of SCN9A mRNA22100608
D000643Ammonium ChlorideAmmonium Chloride affects the expression of SCN9A mRNA16483693
C547126AZM551248AZM551248 results in decreased expression of SCN9A mRNA22323515
D001496BatrachotoxinsBatrachotoxins binds to SCN9A protein21634377
D001496BatrachotoxinsTetracaine inhibits the reaction [Batrachotoxins binds to SCN9A protein]21634377
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of SCN9A mRNA20106945|2163298
D001564Benzo(a)pyreneBenzo(a)pyrene results in increased expression of SCN9A mRNA21839799
C006780bisphenol Abisphenol A results in increased expression of SCN9A mRNA27571134
C006780bisphenol Abisphenol A results in increased expression of SCN9A protein24552547
C546612brevetoxin 3brevetoxin 3 binds to SCN9A protein19486905
C018475butyraldehydebutyraldehyde results in decreased expression of SCN9A mRNA26079696
D002118Calcium[Lithium Chloride results in increased expression of SCN9A protein] which results in increased uptake of Calcium19486905
D002220CarbamazepineCarbamazepine affects the activity of SCN9A protein mutant form19557861
D002220CarbamazepineSCN9A gene mutant form affects the susceptibility to Carbamazepine17145499
D002395Catecholamines[Lithium Chloride results in increased expression of SCN9A protein] which results in increased secretion of Catecholamines19486905
D019327Copper SulfateCopper Sulfate results in decreased expression of SCN9A mRNA19549813
D003471CuprizoneCuprizone affects the expression of SCN9A mRNA27523638
D016572CyclosporineCyclosporine results in decreased expression of SCN9A mRNA25562108|2798913
D002945Cisplatin[Cisplatin co-treated with jinfukang] results in decreased expression of SCN9A mRNA27392435
D002945CisplatinCisplatin results in decreased expression of SCN9A mRNA27392435
D000431Ethanol[Fish Oils co-treated with Ethanol] results in increased expression of SCN9A mRNA17347304
D005395Fish Oils[Fish Oils co-treated with Ethanol] results in increased expression of SCN9A mRNA17347304
D004397FonofosFonofos results in decreased methylation of SCN9A promoter22847954
C544151jinfukang[Cisplatin co-treated with jinfukang] results in decreased expression of SCN9A mRNA27392435
C544151jinfukangjinfukang results in decreased expression of SCN9A mRNA27392435
C561695(+)-JQ1 compound(+)-JQ1 compound results in increased expression of SCN9A mRNA21889194
D018021Lithium Chloride[Lithium Chloride results in decreased activity of GSK3B protein] which results in increased expression of SCN9A mRNA19486905
D018021Lithium ChlorideLithium Chloride results in increased expression of SCN9A mRNA19486905
D018021Lithium ChlorideLithium Chloride results in increased expression of SCN9A protein19486905
D018021Lithium Chloride[Lithium Chloride results in increased expression of SCN9A protein] which results in increased secretion of Catecholamines19486905
D018021Lithium Chloride[Lithium Chloride results in increased expression of SCN9A protein] which results in increased uptake of Calcium19486905
D018021Lithium Chloride[Lithium Chloride results in increased expression of SCN9A protein] which results in increased uptake of Sodium19486905
D008801MexiletineSCN9A mRNA SNP results in increased susceptibility to Mexiletine19162012
C016599mono-(2-ethylhexyl)phthalatemono-(2-ethylhexyl)phthalate results in increased expression of SCN9A mRNA22401849
C561228N-(2-methyl-3-(4-(4-(4-(trifluoromethoxy)benzyloxy)piperidin-1-yl)-1,3,5-triazin-2-ylamino)phenyl)acetamide"N-(2-methyl-3-(4-(4-(4-(trifluoromethoxy)benzyloxy)piperidin-1-yl)-1,3,5-triazin-2-ylamino)phenyl)acetamide results in decreased activity of SCN9A protein"21634377
D009532NickelNickel results in increased expression of SCN9A mRNA25583101
D010278ParathionParathion results in decreased methylation of SCN9A promoter22847954
D011374ProgesteroneProgesterone results in increased expression of SCN9A mRNA19690047
D011441PropylthiouracilPropylthiouracil affects the expression of SCN9A mRNA24780913
D011794QuercetinQuercetin results in decreased expression of SCN9A mRNA21632981
D012530SaxitoxinSaxitoxin binds to SCN9A protein19486905
D012604Scorpion VenomsScorpion Venoms affects the activity of SCN9A protein21887265
D012822Silicon DioxideSilicon Dioxide analog results in decreased expression of SCN9A mRNA25895662
D012964Sodium[Lithium Chloride results in increased expression of SCN9A protein] which results in increased uptake of Sodium19486905
D012964SodiumSCN9A protein results in increased transport of Sodium16020462
D012964SodiumTetrodotoxin inhibits the reaction [SCN9A protein results in increased transport of Sodium]16020462
D012964Sodium[Tetrodotoxin results in decreased activity of [SCN8A protein co-treated with SCN9A protein]] which affects the transport of Sodium23382806
C017947sodium arsenitesodium arsenite affects the methylation of SCN9A gene28589171
C017947sodium arsenitesodium arsenite results in decreased expression of and affects the splicing of SCN9A mRNA25879800
C012568terbufosterbufos results in decreased methylation of SCN9A promoter22847954
D013748TetracaineTetracaine inhibits the reaction [Batrachotoxins binds to SCN9A protein]21634377
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased expression of SCN9A mRNA20106945
D013779TetrodotoxinTetrodotoxin results in decreased activity of SCN9A protein17522141
D013779TetrodotoxinTetrodotoxin inhibits the reaction [SCN9A protein results in increased transport of Sodium]16020462
D013779Tetrodotoxin[Tetrodotoxin results in decreased activity of [SCN8A protein co-treated with SCN9A protein]] which affects the transport of Sodium23382806
D013779TetrodotoxinTetrodotoxin results in decreased activity of SCN9A protein23382806
C012589trichostatin Atrichostatin A results in increased expression of SCN9A mRNA24935251
C016805tris(1,3-dichloro-2-propyl)phosphate"tris(1,3-dichloro-2-propyl)phosphate results in decreased expression of SCN9A mRNA"26179874
D014520UrethaneUrethane results in decreased expression of SCN9A mRNA28818685
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCN9A mRNA"27188386
D014635Valproic AcidValproic Acid affects the expression of SCN9A mRNA25979313
D014635Valproic AcidValproic Acid results in increased expression of SCN9A mRNA19101580|2317975
D014638VanadatesVanadates results in increased expression of SCN9A mRNA22714537
D001335Vehicle EmissionsVehicle Emissions results in decreased methylation of SCN9A gene25560391

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0005244voltage-gated ion channel activity-IEA-  
GO:0005248voltage-gated sodium channel activity-IBA21873635  
GO:0005248voltage-gated sodium channel activity-IDA17145499  
GO:0005261cation channel activity-IBA21873635  
GO:0031402sodium ion binding-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0006814sodium ion transport-TAS7720699  
GO:0006954inflammatory response-IEA-  
GO:0009636response to toxic substance-IEA-  
GO:0009791post-embryonic development-IEA-  
GO:0019228neuronal action potential-IBA21873635  
GO:0019233sensory perception of pain-IMP17145499  
GO:0034765regulation of ion transmembrane transport-IEA-  
GO:0035725sodium ion transmembrane transport-IBA21873635  
GO:0035725sodium ion transmembrane transport-IDA17145499  
GO:0048266behavioral response to pain-IEA-  
GO:0086010membrane depolarization during action potential-IBA21873635  
GO ID GO Term Qualifier Evidence PubMed
GO:0001518voltage-gated sodium channel complex-IEA-  
GO:0005886plasma membrane-IBA21873635  
GO:0005887integral component of plasma membrane-IMP17145499  
GO:0042995cell projection-IEA-  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence
R-HSA-1266738Developmental BiologyIEA
R-HSA-373760L1CAM interactionsIEA
R-HSA-397014Muscle contractionTAS
R-HSA-422475Axon guidanceIEA
R-HSA-445095Interaction between L1 and AnkyrinsIEA
R-HSA-5576891Cardiac conductionTAS
R-HSA-5576892Phase 0 - rapid depolarisationTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
26005122[American Academy of Neurology, Washington, 18-25 April 2015]. (2015 Jun-Jul)Sibon IRev Neurol (Paris)